Compound Profiles
CJC-1295 (without DAC)
Short-Acting Growth Hormone Releasing Hormone Analog
Binds GHRH receptors on somatotroph cells in the pituitary gland, stimulating cAMP production and physiological GH pulses. The brief 30-minute half-life allows pulsatile release versus prolonged elevation.
CJC/IPA Protocol
GHRH/GHRP Combination | Growth Hormone Optimization
CJC-1295 activates GHRH receptors via albumin-binding DAC technology for sustained elevation. Ipamorelin selectively activates ghrelin receptors (GHSR1a) without affecting ACTH/cortisol, preserving natural pulsatile GH patterns.
Combined Organ Load
Shared Safety Flags
Frequently Asked Questions
Can I take CJC-1295 (without DAC) with CJC/IPA Protocol?
Yes, but with caution. Both CJC-1295 (without DAC) and CJC/IPA Protocol affect insulin sensitivity or blood glucose. Monitor fasting glucose and HbA1c. Consider adding an insulin sensitizer (metformin/berberine). Regular monitoring is advised.
Is CJC-1295 (without DAC) and CJC/IPA Protocol safe together?
Based on pharmacological analysis, this combination is considered monitor. However, shared safety flags include: carcinogenic risk, insulin disrupting. Monitor accordingly.
What are the interactions between CJC-1295 (without DAC) and CJC/IPA Protocol?
Both CJC-1295 (without DAC) and CJC/IPA Protocol affect insulin sensitivity or blood glucose. Monitor fasting glucose and HbA1c. Consider adding an insulin sensitizer (metformin/berberine). This assessment has 47% confidence and is inferred from pharmacological mechanism analysis.
This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.